Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.

Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, Yu DM.

Cardiovasc Diabetol. 2014 Feb 5;13:36. doi: 10.1186/1475-2840-13-36.

2.

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.

Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, Zdravkovic M, Strauss BJ, Garber AJ; LEAD-2 and LEAD-3 Study Groups.

Diabetes Obes Metab. 2009 Dec;11(12):1163-72. doi: 10.1111/j.1463-1326.2009.01158.x.

PMID:
19930006
3.
4.

Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.

Santilli F, Simeone PG, Guagnano MT, Leo M, Maccarone MT, Di Castelnuovo A, Sborgia C, Bonadonna RC, Angelucci E, Federico V, Cianfarani S, Manzoli L, Davì G, Tartaro A, Consoli A.

Diabetes Care. 2017 Nov;40(11):1556-1564. doi: 10.2337/dc17-0589. Epub 2017 Sep 14.

PMID:
28912305
5.

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.

6.

Natriuretic peptides as markers of preclinical cardiac disease in obesity.

Grandi AM, Laurita E, Selva E, Piantanida E, Imperiale D, Giovanella L, Guasti L, Venco A.

Eur J Clin Invest. 2004 May;34(5):342-8.

PMID:
15147331
7.

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H, Tanaka E, Kuriyama Y, Miyatake H, Abe M, Umezono T, Fukagawa M.

Intern Med. 2013;52(10):1029-34. Epub 2013 May 15.

8.

Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.

Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ.

Diabetes Care. 2015 Jan;38(1):132-9. doi: 10.2337/dc14-1958. Epub 2014 Nov 20.

PMID:
25414155
9.

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.

Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ.

PLoS One. 2012;7(12):e50117. doi: 10.1371/journal.pone.0050117. Epub 2012 Dec 6.

10.

Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study.

Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, Flyvbjerg A, Faber J.

Metabolism. 2014 Jan;63(1):141-9. doi: 10.1016/j.metabol.2013.09.017. Epub 2013 Oct 17.

PMID:
24140097
11.

Long-term effectiveness and safety of liraglutide in clinical practice.

Ponzani P.

Minerva Endocrinol. 2013 Mar;38(1):103-12.

PMID:
23435446
13.

Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial.

Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, Gao LJ, Yang DH, Zhu DL.

J Diabetes Investig. 2019 Mar;10(2):399-407. doi: 10.1111/jdi.12888. Epub 2018 Aug 16.

14.

Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals.

Cheng S, Fox CS, Larson MG, Massaro JM, McCabe EL, Khan AM, Levy D, Hoffmann U, O'Donnell CJ, Miller KK, Newton-Cheh C, Coviello AD, Bhasin S, Vasan RS, Wang TJ.

Am J Cardiol. 2011 Oct 1;108(7):979-84. doi: 10.1016/j.amjcard.2011.05.033. Epub 2011 Aug 1.

15.

Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.

Feng P, Yu DM, Chen LM, Chang BC, Ji QD, Li SY, Zhu M, Ding SH, Zhang BZ, Wang SL, Li HT, Lin JN, Wang MJ, Guo JC, Liu J, Liu ZD, Wu ST, Yang JH.

Acta Pharmacol Sin. 2015 Feb;36(2):200-8. doi: 10.1038/aps.2014.136. Epub 2015 Jan 26.

16.

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.

Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B.

Diabetes Obes Metab. 2013 Jan;15(1):42-54. doi: 10.1111/j.1463-1326.2012.01673.x. Epub 2012 Sep 9.

PMID:
22862847
17.

Natriuretic peptides in patients with atrial fibrillation.

Wozakowska-Kapłon B, Opolski G, Herman Z, Kosior D.

Cardiol J. 2008;15(6):525-9.

PMID:
19039756
18.

Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.

Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, Avogaro A.

Acta Diabetol. 2013 Dec;50(6):943-9. doi: 10.1007/s00592-013-0489-3. Epub 2013 Jun 11.

PMID:
23754673
19.

Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study.

Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH Jr, de Lemos JA.

Circulation. 2005 Oct 4;112(14):2163-8.

PMID:
16203929
20.

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus.

Yan P, Li L, Yang M, Liu D, Liu H, Boden G, Yang G.

Diabetes Res Clin Pract. 2011 Jun;92(3):368-74. doi: 10.1016/j.diabres.2011.02.030. Epub 2011 Mar 31.

PMID:
21458097

Supplemental Content

Support Center